Verve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Rating of "Hold" by Analysts

Key Points

• Verve Therapeutics has received a consensus rating of "Hold" from nine brokerages, with six analysts recommending to hold and three suggesting to buy the stock.
• The average 12-month target price for Verve Therapeutics among analysts is $14.57, reflecting varying outlooks on the company's performance.
• Recent changes in institutional holdings include a significant increase by Farther Finance Advisors, which raised its stake by 8,746.4% during the second quarter.

Shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Get Free Report) have received a consensus rating of "Hold" from the nine research firms that are covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $14.57.

VERV has been the subject of several research analyst reports. Guggenheim lifted their price target on Verve Therapeutics from $18.00 to $24.00 and gave the stock a "buy" rating in a research note on Tuesday, April 15th. William Blair downgraded Verve Therapeutics from a "strong-buy" rating to a "market perform" rating in a research report on Tuesday, June 17th. Lifesci Capital lowered shares of Verve Therapeutics from a "strong-buy" rating to a "hold" rating and set a $12.00 price objective for the company. in a report on Wednesday, June 18th. Wall Street Zen raised shares of Verve Therapeutics to a "hold" rating in a research note on Saturday, July 26th. Finally, Canaccord Genuity Group lowered Verve Therapeutics from a "strong-buy" rating to a "hold" rating and lowered their price target for the company from $39.00 to $13.00 in a research report on Tuesday, June 17th.

Institutional Trading of Verve Therapeutics

Institutional investors have recently bought and sold shares of the stock. HighTower Advisors LLC acquired a new position in Verve Therapeutics during the fourth quarter worth $115,000. Swiss National Bank raised its position in Verve Therapeutics by 15.6% in the 4th quarter. Swiss National Bank now owns 133,100 shares of the company's stock valued at $751,000 after purchasing an additional 18,000 shares during the last quarter. Commonwealth Equity Services LLC grew its holdings in shares of Verve Therapeutics by 17.6% in the 4th quarter. Commonwealth Equity Services LLC now owns 31,952 shares of the company's stock worth $180,000 after acquiring an additional 4,785 shares during the period. Teacher Retirement System of Texas boosted its position in shares of Verve Therapeutics by 37.4% in the 4th quarter. Teacher Retirement System of Texas now owns 20,254 shares of the company's stock worth $114,000 after buying an additional 5,512 shares in the last quarter. Finally, American Century Companies Inc. grew its position in shares of Verve Therapeutics by 12.3% in the fourth quarter. American Century Companies Inc. now owns 127,464 shares of the company's stock valued at $719,000 after purchasing an additional 13,916 shares during the last quarter. 97.11% of the stock is currently owned by institutional investors and hedge funds.

Verve Therapeutics Price Performance

VERV remained flat at $11.13 during trading on Monday. Verve Therapeutics has a 1 year low of $2.86 and a 1 year high of $11.40. The company's 50 day moving average is $9.03 and its 200 day moving average is $6.92. The company has a market cap of $992.13 million, a PE ratio of -5.27 and a beta of 2.23.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.36. The firm had revenue of $32.98 million during the quarter, compared to the consensus estimate of $7.13 million. Verve Therapeutics had a negative net margin of 303.64% and a negative return on equity of 35.81%. On average, research analysts expect that Verve Therapeutics will post -2.49 EPS for the current year.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.